Clinical trials
Observational Hemophilia A trials in the Netherlands
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Unknown status | 1 |
| Suspended | 1 |
| Terminated | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 4 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 2 |
| Novo Nordisk A/S | 2 |
| Radboud University Medical Center | 2 |
| Baxalta now part of Shire | 1 |
| Fondazione Angelo Bianchi Bonomi | 1 |
| PedNet Haemophilia Research Foundation | 1 |
| Swedish Orphan Biovitrum | 1 |
| The University of Texas Health Science Center, Houston | 1 |
| UMC Utrecht | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemophilia A | 18 |
| Hemophilia B | 4 |
| Cardiovascular Diseases | 1 |
| Diabetes Mellitus | 1 |
| Disease | 1 |
| Hemorrhage | 1 |
| Hypercholesterolemia | 1 |
| Hypertension | 1 |
| Obesity | 1 |
| von Willebrand Disease, Type 3 | 1 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.